Analysis of Forced Degradation Products in Rilpivirine using RP-HPLC and Peak Purity Evaluation

• Published in: Oriental journal of chemistry Vol. 39; no. 6; pp. 1534 - 1539
• Main Authors: Ramarao, Abburi, Rao, Guttikonda Venkata, Chinnamaneni, Satya Vani, Sri, Komati Navya, Tej, Mandava Bhagya, Rao, Gollammudi Padma, Abbaraju, V D N Kumar, Basaveswarao RaoBasaveswarao Rao, Mandava Venkata
• Format: Journal Article
• Language: English
• Published: 27.12.2023
• ISSN: 0970-020X; 2231-5039
• DOI: 10.13005/ojc/390613

The primary objective of this research was to delve into the forced degradation products of Rilpivirine hydrochloride (RLP HCl), a crucial non-nucleoside reverse transcriptase inhibitor employed inmanagement of epidemic disease named HIV-1. The investigation utilised the probable of RP-HPLC in tandem with peak purity assessment .In order to simulate conceivable degradation pathways, the study encompassed a gamut of stress conditions like acidic, alkaline, oxidative , thermal and photolytic environments. Authors used Agilent zorbaxEclipse XDB C18 column (150x2.1mm, 1.8µm), RLP and impurities were separated. Buffer as pH of 3.0 and acetonitrile in gradient mode (68:32v/v), flow rate of 0.55ml/min. Volume injected is 3µL and detection wavelength is 220 nm. Temperature is maintained at 55oC by 70:30v/v mixture of water and acetonitrile.System suitability was erect to be within the limits. The average percentage recoveries for impurities were 98% to 101%.The outcomes of this meticulous study unveiled the susceptibilities of RLP to a spectrum of stress factors, in the generation of impurity profile RLP-Amide A, RLP-Amide Band Z-RLP with peak purities. The forced degradation tests demonstrate that the peak of RP-HPLC is spectroscopically pure in all stressed conditions. All degradation products are separated from the main peak and do not interfere with main substance. This exploration not only augments the comprehension of RLP’s stability profile but also underscores the pivotal role of analytical techniques in upholding the safety and efficacy benchmarks of pharmaceutical formulations.